广誉远：控股子公司取得药品注册证书

Group 1 - The core point of the article is that Guangyuyuan has received approval from the National Medical Products Administration for the registration of Banxia Xiexin Decoction granules, which is a significant development for the company [1] - Guangyuyuan's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 89.39%, while other businesses contribute 3.85%, and health wine accounts for 3.29% [1] - As of the report, Guangyuyuan's market capitalization stands at 8.9 billion yuan [1] Group 2 - The article also mentions that the real estate sector is facing challenges, with a notable 2 billion yuan debt maturing and ongoing negotiations for debt extension, alongside over 10 billion yuan in public debts due next year [1]